Sales of Novo Nordisk’s fast-growing GLP-1 agonist drugs for diabetes and obesity may be held back by supply constraints, but feverish demand is still driving strong growt
The EMA’s safety committee has said that, after a review of available data, it has found no evidence that GLP-1 agonist drugs such as Novo Nordisk’s Ozempic and Eli Lilly’
Earlier this month, pharmaphorum editor-in-chief Jonah Comstock had the opportunity to visit the headquarters of the Novo Nordisk Foundation in Copenhagen, Denmark to talk to several innova
Novo Nordisk has agreed a $1.3 billion deal with Singapore’s KBP Biosciences to buy ocedurenone, a drug for uncontrolled hypertension that ties in with its ongoing efforts
Novo Nordisk has halted a phase 3 trial of its Ozempic formulation of GLP-1 agonist semaglutide in patients with type 2 diabetes and chronic kidney disease (CKD) early aft